Australia - angielski - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadoteric acid, quantity: 279.32 mg/ml - injection, solution - excipient ingredients: meglumine; tetraxetan; water for injections - dotagraf is indicated, in adults and children, for use with magnetic resonance imaging to provide contrast enhancement for intracranial and spinal lesions with abnormal blood brain barrier or abnormal vascularity, and for whole body imaging (see section 5.1 pharmacodynamic properties ? clinical trials).

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)); hepatitis a virus formaldehyde inactivated, gbm strain 160 u - solution for injection - active: salmonella typhi vi polysaccharide 25ug (salmonella typhi vi polysaccharide (ty2 strain)) excipient: dibasic sodium phosphate dihydrate monobasic sodium phosphate dihydrate sodium chloride water for injection active: hepatitis a virus formaldehyde inactivated, gbm strain 160 u excipient: aluminium hydroxide as aluminium formaldehyde medium 199 phenoxyethanol as 2-phenoxyethanol solution 2.5µl - vivaxim® is indicated for simultaneous active immunisation against typhoid fever and hepatitis a virus infections in subjects aged 16 and older.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.669 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: benzenesulfonic acid; water for injections - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - cisatracurium besilate, quantity: 0.268 % w/v - solution - excipient ingredients: water for injections; benzenesulfonic acid - cisatracurium-aft is indicated for use during surgical and other procedures and in intensive care to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation. it is used as an adjunct to general anaesthesia, or sedation in the intensive care unit.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; water for injections; glycerol; sodium hydroxide; soya oil; egg lecithin; oleic acid - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; egg lecithin; sodium hydroxide; water for injections; oleic acid; glycerol; soya oil - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: medium chain triglycerides; sodium hydroxide; water for injections; glycerol; oleic acid; soya oil; egg lecithin - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - propofol, quantity: 10 g/l - injection, emulsion - excipient ingredients: glycerol; sodium hydroxide; egg lecithin; medium chain triglycerides; soya oil; oleic acid; water for injections - induction of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short-acting intravenous anaesthetic agent suitable for induction of general anaesthesia in adults and children aged one month and older.,maintenance of general anaesthesia in children and adults,fresofol (1 percent) mct / lct is a short acting intravenous anaesthetic agent suitable for maintenance of general anaesthesia in adults and children aged 3 years and older.,fresofol (1 percent) mct / lct may also be used for maintenance of general anaesthesia in children aged from one month to 3 years for procedures not exceeding 60 minutes, unless alternative anaesthetic agents should be avoided.,fresofol (1 percent) mct / lct has no analgesic properties. ,sedation during intensive care in adults,fresofol (1 percent) mct / lct may also be used in adults for sedation of ventilated patients receiving intensive care.,conscious sedation for surgical and diagnostic procedures in adults,fresofol (1 percent) mct / lct may also be used in adults for monitored conscious sedation for surgical and diagnostic procedures.